KalVista Pharmaceuticals (KALV) & Auxilium Pharmaceuticals (AUXL) Critical Comparison
KalVista Pharmaceuticals (NASDAQ: KALV) and Auxilium Pharmaceuticals (NASDAQ:AUXL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.
This is a breakdown of current ratings and price targets for KalVista Pharmaceuticals and Auxilium Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
KalVista Pharmaceuticals presently has a consensus target price of $27.00, indicating a potential upside of 114.29%. Given KalVista Pharmaceuticals’ higher probable upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Auxilium Pharmaceuticals.
Valuation & Earnings
This table compares KalVista Pharmaceuticals and Auxilium Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$625,000.00||195.81||-$16.21 million||N/A||N/A|
Auxilium Pharmaceuticals has higher revenue, but lower earnings than KalVista Pharmaceuticals.
Institutional and Insider Ownership
75.7% of KalVista Pharmaceuticals shares are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares KalVista Pharmaceuticals and Auxilium Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
KalVista Pharmaceuticals beats Auxilium Pharmaceuticals on 6 of the 8 factors compared between the two stocks.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Auxilium Pharmaceuticals Company Profile
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.